• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, August 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

15-year study finds treatment gaps exist for patients with peripheral arterial disease

Bioengineer by Bioengineer
November 17, 2019
in Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Intermountain Healthcare

Peripheral arterial disease (PAD) is a progressive and life-threatening form of atherosclerosis that narrows the arteries serving the legs, arms, chest, and abdominal organs. It affects more than 8.5 million people in the United States, including 10 to 20 percent of individuals over 60 years old.

Outcomes of PAD patients are worse than those with coronary disease or cerebrovascular disease, emphasizing the importance of attention to their treatment.Like other kinds of atherosclerotic cardiovascular diseases, it should be treated with high-intensity doses of statins.

However, a new 15-year study by researchers at the Intermountain Healthcare Heart Institute in Salt Lake City found that PAD patients may not be prescribed these life-saving medications at the same rate as for other atherosclerotic conditions, such as heart attack or stroke.

“As a profession we focus so much on coronary disease that we may be not be optimally treating patients with PAD, especially when it comes to statin prescription,” said Jeffrey L. Anderson, principal investigator of the study and distinguished clinical and research physician at the Intermountain Healthcare Heart Institute. “However, we found that over time, statin prescription rates across our healthcare system have increased for PAD patients, and with it, PAD patient outcomes have improved. Despite this, there remains a significant treatment gap, so much more progress is needed.”

In the study, researchers identified 4,333 patients who had a first encounter with PAD (idisease in the aorta and lower extremities) between January 1, 1999 and December 31, 2013, and survived that event.

They then were followed for at least three years or until their death. Overall, statin prescription was associated with a reduced 3-year rate of subsequent heart attack, stroke, or death, from 23.5% to 18.9%, and it was only 14.3% if the prescription was for a high-intensity statin. Unfortunately, only one-third of patients overall had been prescribed a statin at discharge after their PAD event, and only 11% were prescribed a high-intensity statin.

The Intermountain researchers then gave attention to the treatment trend over 15 years. From 1999 through 2013, a statin prescription increased in five-year increments from 17% to 37% to 48%, indicating steady progress toward the 100% ultimate treatment goal. However, the most recent value of 48% for PAD still lags significantly behind values of 74% for cerebrovascular disease (e.g., stroke) patients and 93% for coronary disease (e.g., heart attack) patients.

Findings from the study will be presented at the 2019 American Heart Association Scientific Sessions Philadelphia on Nov. 17, 2019.

Dr. Anderson noted the favorable progress in PAD treatment, but he highlighted the remaining large treatment gap when compared to coronary and stroke patients, showing that more work needs to be done in statin prescribing for patients with PAD.

“We’re doing much better in terms of treating these patients with statins, but there’s still a need for more attention to this group,” he said. “More than 90 percent of our heart attack patients are prescribed statins. We need to keep focusing on PAD patients to get them to the right physicians who are fully aware of the need to treat them as high-risk patients and to get their statin percentages also up into the mid-90s. These patients represent the highest risk atherosclerosis group, but they also are the group that stands to benefit the most from statin therapy.”

###

Other members of the research team included: Kirk U. Knowlton, Heidi T. May, Tami L. Bair, Viet Le, Donald L. Lappe, and Joseph B. Muhlestein.

Media Contact
Jess C. Gomez
[email protected]
801-718-8495

Tags: CardiologyCholesterolDiabetesDiagnosticsInternal MedicineMedicine/HealthMetabolism/Metabolic DiseasesPhysiologyStroke
Share12Tweet8Share2ShareShareShare2

Related Posts

Erythritol Levels in Korean Foods Analyzed

Erythritol Levels in Korean Foods Analyzed

August 6, 2025
blank

Metazoan Parasite Diversity in Little Tunny, Tunisia

August 6, 2025

Unraveling Microbial Mysteries in Heavy Crude Oil

August 6, 2025

Building Proteins Like Dominoes: How Artificial Enzymes Are Assembled from Modular Parts

August 6, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    74 shares
    Share 30 Tweet 19
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Erythritol Levels in Korean Foods Analyzed

Zhou Secures Funding to Develop Innovative Performance Profiling and Analysis Infrastructure for Scientific Deep Learning Workloads

Advances in Bone Microstructure Reveal Forensic Clues

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.